Purpose: To evaluate the safety and efficacy of intralesional triamcinolone ac etonide (TA) injection in primary and recurrent chalazia. Design: Retrospective, interventional, consecutive case series. Participants: On...Purpose: To evaluate the safety and efficacy of intralesional triamcinolone ac etonide (TA) injection in primary and recurrent chalazia. Design: Retrospective, interventional, consecutive case series. Participants: One hundred forty-seven patients with primary or recurrent chalazia (155 cases) treated at the oculopla stic clinic at the Jules Stein Eye Institute between January 1, 2000, and Decemb er 31, 2003. Methods: Patients received an intralesional injection of 0.1 to 0.2 ml TA (40 mg/ml). Data regarding lesion size, including digital color photograp hy, lesion regression or recurrence, and complete ophthalmic examination, were r ecorded at the time of injection and at different intervals until resolution or surgical excision. Success was defined as at least an 80%decrease in size with no recurrence. If the lesion recurred or regression was minimal (< 50%), furthe r injections were given as needed. Patients who declined injection or who did no t respond to 2 to 3 injections were referred for surgical excision and drainage. Main Outcome Measures: Lesion size, clinical resolution,展开更多
文摘Purpose: To evaluate the safety and efficacy of intralesional triamcinolone ac etonide (TA) injection in primary and recurrent chalazia. Design: Retrospective, interventional, consecutive case series. Participants: One hundred forty-seven patients with primary or recurrent chalazia (155 cases) treated at the oculopla stic clinic at the Jules Stein Eye Institute between January 1, 2000, and Decemb er 31, 2003. Methods: Patients received an intralesional injection of 0.1 to 0.2 ml TA (40 mg/ml). Data regarding lesion size, including digital color photograp hy, lesion regression or recurrence, and complete ophthalmic examination, were r ecorded at the time of injection and at different intervals until resolution or surgical excision. Success was defined as at least an 80%decrease in size with no recurrence. If the lesion recurred or regression was minimal (< 50%), furthe r injections were given as needed. Patients who declined injection or who did no t respond to 2 to 3 injections were referred for surgical excision and drainage. Main Outcome Measures: Lesion size, clinical resolution,
